TP53 and acute myeloid leukemia: In summary, the inability of CAR T-cells to eradicate MOLM13-TP53−/− AML cells in vitro likely involves sustained activating CAR signaling, exacerbated CAR T-cell exhaustion, enhanced trogocytosis, and decreased proliferation.